Jul. 16, 2020
NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19
With resurgent COVID-19, enrollment has accelerated in Miami, Houston, and Irvine.